Kepplah
Related Articles
Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau disease who require treatment for associated renal carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors.
Medication Pearl of the day: Belzutifan (Welireg)
Indication: Belzutif is a hypoxia-inducible factor inhibitor indicated for the treatment of adult patients with von Hippel-Lindau disease who require treatment for associated renal carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors, not requiring no immediate surgery.
Overview:
- Dosage: The recommended dosage of belzutifanis 120 mg taken orally once daily with or without food.
- Dosage forms:Tablets 40 mg.
- Adverse Events (AEs): The most common AEs (≥ 25%), including laboratory abnormalities, were decreased hemoglobin, anemia, fatigue, increased creatinine, headache, dizziness, increased blood blood sugar and nausea.
- Action mechanism: Belzutifan is a hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor. HIF-2α is a transcription factor that plays a role in the detection of oxygen by regulating genes that promote adaptation to hypoxia.
- Maker: Merck
Sources:
